Market Place

Market Place

Market Place

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search
All
API
FDF
Price
Services
Excipients
Enquiries

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Price
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    pipeline-prospector-insert
    X

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    Country filter
      News Type filter
        Company filter
          Product Type filter
            Deal Size filter
              refresh

              Product Type Full Screen

              Companies Full Screen

              ARCA Biopharma

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              UNITED KINGDOM United Kingdom

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              IFT Annual Expo

              Participation Not Confirmed

              Update your events

              ARCA Biopharma Announces $9.4 Million Registered Direct Offering

              Contact the Supplier

              Lead Product(s): rNAPc2

              Therapeutic Area: Hematology Product Name: Undisclosed

              Highest Development Status: Preclinical Product Type: Large molecule

              Partner/Sponsor/Collaborator: JonesTrading Institutional Services

              Deal Size: $9.4 million Upfront Cash: Undisclosed

              Deal Type: Public Offering June 01, 2020

              Details:

              ARCA anticipates that the net proceeds from this offering will be used to initiate its clinical trial of AB201 and for working capital and general corporate purposes.

              ARCA Biopharma

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              UNITED KINGDOM United Kingdom

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              IFT Annual Expo

              Participation Not Confirmed

              Update your events

              ARCA biopharma Announces AB201 Development Program for Treatment of COVID-19 Associated Coagulopathy

              Contact the Supplier

              Lead Product(s): rNAPc2

              Therapeutic Area: Hematology Product Name: Undisclosed

              Highest Development Status: Preclinical Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable May 28, 2020

              Details:

              AB201 (rNAPc2) is being developed as a potential treatment for COVID Associated Coagulopathy, a condition characterized by abnormal blood clotting in patients with COVID-19.

              PharmaCompass__DigitalAd